SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

被引:482
|
作者
Chow, Pierce K. H. [1 ,2 ]
Gandhi, Mihir [2 ,3 ]
Tan, Say-Beng [3 ,4 ]
Khin, Maung Win [8 ]
Khasbazar, Ariunaa [9 ]
Ong, Janus [10 ,11 ]
Choo, Su Pin [1 ]
Cheow, Peng Chung [5 ]
Chotipanich, Chanisa [15 ]
Lim, Kieron [6 ]
Lesmana, Laurentius A. [16 ,17 ]
Manuaba, Tjakra W. [18 ]
Yoong, Boon Koon [19 ]
Raj, Aloysius [20 ]
Law, Chiong Soon [21 ]
Cua, Ian H. Y. [12 ]
Lobo, Rolley R. [13 ]
Teh, Catherine S. C. [14 ]
Kim, Yun Hwan [22 ]
Jong, Yun Won [23 ]
Han, Ho-Seong [24 ]
Bae, Si-Hyun [25 ]
Yoon, Hyun-Ki [26 ]
Lee, Rheun-Chuan [27 ]
Hung, Chien-Fu [29 ]
Peng, Cheng-Yuan [30 ]
Liang, Po-Chin [28 ]
Bartlett, Adam [31 ]
Kok, Kenneth Y. Y. [32 ]
Thng, Choon-Hua [1 ]
Low, Albert Su-Chong [5 ]
Goh, Anthony S. W. [5 ]
Tay, Kiang Hiong [5 ]
Lo, Richard H. G. [5 ]
Goh, Brian K. P. [5 ]
Ng, David C. E. [5 ]
Lekurwale, Ganesh [3 ]
Liew, Wei Ming [3 ]
Gebski, Val [33 ]
Mak, Kenneth S. W. [7 ]
Soo, Khee Chee [1 ]
机构
[1] Natl Canc Ctr Singapore, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Singapore Clin Res Inst, Singapore, Singapore
[4] SingHealth, Singapore, Singapore
[5] Singapore Gen Hosp, Singapore, Singapore
[6] Natl Univ Singapore Hosp, Singapore, Singapore
[7] Khoo Teck Puat Hosp, Singapore, Singapore
[8] Yangon GI & Liver Ctr, Yangon, Myanmar
[9] Natl Canc Ctr Mongolia, Ulaanbaatar, Mongolia
[10] Med City, Pasig, Philippines
[11] Univ Philippines Manila, Manila, Philippines
[12] St Lukes Med Ctr Global City, Taguig, Philippines
[13] Davao Doctors Hosp, Davao, Philippines
[14] Makati Med Ctr, Makati, Philippines
[15] Chulabhorn Hosp, Bangkok, Thailand
[16] Cipto Mangunkusumo Hosp, Jakarta, Indonesia
[17] Univ Indonesia, Jakarta, Indonesia
[18] Sanglah Hosp, Denpasar, Indonesia
[19] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[20] Penang Adventist Hosp, George Town, Malaysia
[21] Sarawak Gen Hosp, Kuching, Malaysia
[22] Korea Univ, Anam Hosp, Seoul, South Korea
[23] Severance Hosp, Seoul, South Korea
[24] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[25] Seoul St Marys Hosp, Seoul, South Korea
[26] Asan Med Ctr, Seoul, South Korea
[27] Taipei Vet Gen Hosp, Taipei, Taiwan
[28] Natl Taiwan Univ Hosp, Taipei, Taiwan
[29] Chang Gung Mem Hosp, Linkou Branch, Taoyuan, Taiwan
[30] China Med Univ Hosp, Taichung, Taiwan
[31] Auckland City Hosp, Auckland, New Zealand
[32] Brunei Canc Ctr, Jerudong, Brunei
[33] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Camperdown, NSW, Australia
关键词
Y-90; MICROSPHERES; RADIOEMBOLIZATION; RADIOTHERAPY; MANAGEMENT; PATTERNS; SURVIVAL; OUTCOMES; SARAH;
D O I
10.1200/JCO.2017.76.0892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeSelective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC.Patients and MethodsSIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (Y-90) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population.ResultsA total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs.ConclusionIn patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.
引用
收藏
页码:1913 / +
页数:12
相关论文
共 50 条
  • [31] Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia
    Liu, David M.
    Leung, Thomas Wt
    Chow, Pierce Kh
    Ng, David Ce
    Lee, Rheun-Chuan
    Kim, Yun Hwan
    Mao, Yilei
    Cheng, Yu-Fan
    Teng, Gao-Jun
    Lau, Wan Yee
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 102
  • [32] Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia
    Liu, David M.
    Leung, Thomas W. T.
    Chow, Pierce K. H.
    Ng, David C. E.
    Lee, Rheun-Chuan
    Kim, Yun Hwan
    Mao, Yilei
    Cheng, Yu-Fan
    Teng, Gao-Jun
    Lau, Wan Yee
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 102
  • [33] Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma
    Park, Woo Daniel
    Li, Bob T.
    Maher, Richard
    Samra, Jaswinder S.
    Clarke, Stephen
    Bernard, Elizabeth J.
    Bailey, Dale L.
    Pavlakis, Nick
    OXFORD MEDICAL CASE REPORTS, 2015, (02): : 194 - 195
  • [34] Selective internal radiation therapy (SIRT) for hepatocellular carcinoma: the SCGH experience
    Khoo, T.
    Adams, L. A.
    Jeffrey, G.
    Garas, G.
    Macquillan, G.
    Samuelson, S.
    Tibballs, J.
    Wallace, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 57 - 57
  • [35] Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma
    Anne M. Horgan
    Laura A. Dawson
    Anand Swaminath
    Jennifer J. Knox
    Journal of Gastrointestinal Cancer, 2012, 43 (2) : 344 - 348
  • [36] Concurrent Versus Sequential Sorafenib Therapy in Combination With Radiation for Hepatocellular Carcinoma: A Preclinical Study
    Wild, A.
    Gandhi, N.
    Aziz, K. A.
    Chettiar, S. T.
    Gajula, R. P.
    Kumar, R.
    Torbenson, M. S.
    Hales, R. K.
    Herman, J. M.
    Tran, P. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S337 - S337
  • [37] Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma
    Rognoni, Carla
    Barcellona, Maria Rosa
    Bargellini, Irene
    Bavetta, Maria Grazia
    Bello, Marilena
    Brunetto, Maurizia
    Carucci, Patrizia
    Cioni, Roberto
    Crocetti, Laura
    D'Amato, Fabio
    D'Amico, Mario
    Deagostini, Simona
    Deandreis, Desiree
    De Simone, Paolo
    Doriguzzi, Andrea
    Finessi, Monica
    Fonio, Paolo
    Grimaldi, Serena
    Ialuna, Salvatore
    Lagattuta, Fabio
    Masi, Gianluca
    Moreci, Antonio
    Scalisi, Daniele
    Virdone, Roberto
    Tarricone, Rosanna
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy
    Franze, Maria Stella
    Vigneron, Paul
    Sessa, Anna
    Saitta, Carlo
    Chalaye, Julia
    Tacher, Vania
    Luciani, Alain
    Regnault, Helene
    Bejan, Ancuta
    Rhaiem, Rami
    Sommacale, Daniele
    Leroy, Vincent
    Brustia, Raffaele
    Raimondo, Giovanni
    Amaddeo, Giuliana
    ANNALS OF HEPATOLOGY, 2025, 30 (01)
  • [39] NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma
    Venerito, Marino
    Pech, Maciej
    Canbay, Ali
    Donghia, Rossella
    Guerra, Vito
    Chatellier, Gilles
    Pereira, Helena
    Gandhi, Mihir
    Malfertheiner, Peter
    Chow, Pierce K. H.
    Vilgrain, Valerie
    Ricke, Jens
    Leandro, Gioacchino
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (12) : 1736 - 1742
  • [40] External Beam Radiation Therapy or Selective Internal Radiation Therapy? A Comparison of Treatment Outcomes for Hepatocellular Carcinoma
    Oladeru, O. T.
    Miccio, J. A.
    Yang, J.
    Xue, Y.
    Ryu, S.
    Stessin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E123 - E123